[HTML][HTML] Controlling timing and location in vaccines
Vaccines are one of the most powerful technologies supporting public health. The adaptive
immune response induced by immunization arises following appropriate activation and …
immune response induced by immunization arises following appropriate activation and …
[HTML][HTML] A brief history of the global effort to develop a preventive HIV vaccine
J Esparza - Vaccine, 2013 - Elsevier
Soon after HIV was discovered as the cause of AIDS in 1983–1984, there was an
expectation that a preventive vaccine would be rapidly developed. In trying to achieve that …
expectation that a preventive vaccine would be rapidly developed. In trying to achieve that …
Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection
TR Fouts, K Bagley, IJ Prado, KL Bobb… - Proceedings of the …, 2015 - National Acad Sciences
A guiding principle for HIV vaccine design has been that cellular and humoral immunity work
together to provide the strongest degree of efficacy. However, three efficacy trials of Ad5 …
together to provide the strongest degree of efficacy. However, three efficacy trials of Ad5 …
Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines
Animal and human data from various viral infections and vaccine studies suggest that
nonneutralizing antibodies (nNAb) without neutralizing activity in vitro may play an important …
nonneutralizing antibodies (nNAb) without neutralizing activity in vitro may play an important …
RNA interference approaches for treatment of HIV-1 infection
ML Bobbin, JC Burnett, JJ Rossi - Genome medicine, 2015 - Springer
HIV/AIDS is a chronic and debilitating disease that cannot be cured with current antiretroviral
drugs. While combinatorial antiretroviral therapy (cART) can potently suppress HIV-1 …
drugs. While combinatorial antiretroviral therapy (cART) can potently suppress HIV-1 …
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
A Valentin, C Bergamaschi, M Rosati, M Angel… - Frontiers in …, 2022 - frontiersin.org
Immunogenicity of HIV-1 mRNA vaccine regimens was analyzed in a non-human primate
animal model. Rhesus macaques immunized with mRNA in lipid nanoparticle (mRNA/LNP) …
animal model. Rhesus macaques immunized with mRNA in lipid nanoparticle (mRNA/LNP) …
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques
Background None of the HIV T-cell vaccine candidates that have reached advanced clinical
testing have been able to induce protective T cell immunity. A major reason for these failures …
testing have been able to induce protective T cell immunity. A major reason for these failures …
Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
B cell follicles in secondary lymphoid tissues represent an immune privileged sanctuary for
AIDS viruses, in part because cytotoxic CD8+ T cells are mostly excluded from entering the …
AIDS viruses, in part because cytotoxic CD8+ T cells are mostly excluded from entering the …
Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge
We compare immunogenicity and protective efficacy of an HIV vaccine comprised of env and
gag DNA and Env (Envelope) proteins by co-administration of the vaccine components in …
gag DNA and Env (Envelope) proteins by co-administration of the vaccine components in …
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
NG Rouphael, C Morgan, SS Li… - The Journal of …, 2019 - Am Soc Clin Investig
BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in
humans. Attempting to build upon RV144 immune responses, we conducted a phase 1 …
humans. Attempting to build upon RV144 immune responses, we conducted a phase 1 …